Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue (2016 - 2026)

Ani Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $247.1 million for Q4 2025.

  • On a quarterly basis, Revenue rose 29.64% to $247.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $883.4 million, a 43.78% increase, with the full-year FY2025 number at $883.4 million, up 43.78% from a year prior.
  • Revenue hit $247.1 million in Q4 2025 for Ani Pharmaceuticals, up from $227.8 million in the prior quarter.
  • Over the last five years, Revenue for ANIP hit a ceiling of $247.1 million in Q4 2025 and a floor of $11.2 million in Q1 2021.
  • Historically, Revenue has averaged $123.7 million across 5 years, with a median of $124.1 million in 2023.
  • Biggest five-year swings in Revenue: tumbled 77.5% in 2021 and later surged 475.69% in 2022.
  • Tracing ANIP's Revenue over 5 years: stood at $60.9 million in 2021, then soared by 54.66% to $94.2 million in 2022, then soared by 39.71% to $131.7 million in 2023, then skyrocketed by 44.75% to $190.6 million in 2024, then grew by 29.64% to $247.1 million in 2025.
  • Business Quant data shows Revenue for ANIP at $247.1 million in Q4 2025, $227.8 million in Q3 2025, and $211.4 million in Q2 2025.